Saflufenacil has low acute toxicity via the oral, dermal and inhalation routes of exposure (Toxicity category III or IV). It is slightly irritating to the eye (Toxicity category III). It is neither a dermal irritant nor sensitizer US EPA, 2009;APVMA, 2012).
Saflufenacil acts through the inhibition of protoporphyrinogen oxidase (PPO), resulting in cell membrane damage and subsequent plant death.
Repeat dose studies in laboratory animals indicated that the primary target organ is the hematopoietic system. Protoporphyrinogen Oxidase (PPO) inhibition in mammals may disrupt heme synthesis, which in turn causes anemia characterized by decreased hematological parameters [decreased red blood cells . . .
Please Subscribe to continue reading
